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Abstract
Background: Correction of metabolic acidosis (MA) with nutritional therapy or bicarbonate administration is widely
used in chronic kidney disease (CKD) patients. However, it is unknown whether these interventions reduce insulin
resistance (IR) in diabetic patients with CKD. We sought to evaluate the effect of MA correction on endogenous
insulin action in diabetic type 2 (DM2) CKD patients.
Methods: A total of 145 CKD subjects (83 men e 62 women) with DM2 treated with oral antidiabetic drugs were
included in the study and followed up to 1 year. All patients were randomly assigned 1:1 to either open-label (A)
oral bicarbonate to achieve serum bicarbonate levels of 24–28 mmol/L (treatment group) or (B) no treatment
(control group). The Homeostatic model assessment (HOMA) index was used to evaluate IR at study inception and
conclusion. Parametric and non-parametric tests as well as linear regression were used.
Results: At baseline no differences in demographic and clinical characteristics between the two groups
was observed. Average dose of bicarbonate in the treatment group was 0.7 ± 0.2 mmol/kg. Treated
patients showed a better metabolic control as confirmed by lower insulin levels (13.4 ± 5.2 vs 19.9 ± 6.3;
for treated and control subjects respectively; p < 0.001), Homa-IR (5.9[5.0-7.0] vs 6.3[5.3–8.2]; p = 0.01) and
need for oral antidiabetic drugs. The serum bicarbonate and HOMA-IR relationship was non-linear and
the largest HOMA-IR reduction was noted for serum bicarbonate levels between 24 and 28 mmol/l.
Adjustment for confounders, suggests that serum bicarbonate rather than treatment drives the effect on
HOMA-IR.
Conclusions: Serum bicarbonate is related to IR and the largest HOMA-IR reduction is noted for serum bicarbonate
between 24 and 28 mmol/l. Treatment with bicarbonate influences IR. However, changes in serum bicarbonate
explains the effect of treatment on HOMA index. Future efforts are required to validate these results in diabetic and
non-diabetic CKD patients.
Trial registration: The trial was registered at www.clinicaltrial.gov (Use of Bicarbonate in Chronic Renal Insufficiency
(UBI) study - NCT01640119)
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Background
Incidence of chronic kidney disease (CKD) as well as the
prevalence of diabetic subjects among CKD patients are
steadily increasing [1, 2]. As renal function declines,
metabolic acidosis and insulin resistance (IR) commonly
arise. Among others, these metabolic complications are
associated with serious consequences on bones and nu-
tritional status [3, 4] and likely contribute to some of the
abysmal risk of death associated with CKD.
Insulin resistance (IR) is characterized by suboptimal
biological responses of the liver, skeletal muscle and adi-
pose tissue to normal amounts of insulin secreted [4].
Conditions such as metabolic acidosis, anemia, inflamma-
tion, hyperactivity of the Renin-Angiotensin-Aldosterone
System (RAAS), vitamin D deficiency, physical inactivity,
excess of fat mass as well as nitrogen catabolites accumu-
lation have all been implicated in IR in CKD subjects [5].
Notably, several clinical consequences have been linked to
IR. Indeed, IR may promote endothelial dysfunction and
portends increased cardiovascular mortality. Although evi-
dence is not conclusive, some data also suggest that IR is a
harbinger of CKD incidence and progression. Based on
these lines of evidence, it is conceivable that IR represents
a modifiable risk factor and a potential therapeutic target
to improve CKD outcome [4–6].
The association between metabolic acidosis, IR and
the cardiovascular risk has been documented in the sci-
entific literature since 1924 [7]. However, in spite of the
fact that correction of metabolic acidosis with nutritional
therapy and/or oral administration of sodium bicarbon-
ate in CKD is widely used [8–10], it is unknown whether
correction of metabolic acidosis reduces IR and/or im-
proves insulin effects on target cells in diabetic subjects.
We aim to evaluate whether metabolic acidosis cor-
rection by sodium bicarbonate administration may
improve peripheral endogen insulin utilization by tar-
get organs in diabetic subjects with CKD treated with
oral antidiabetic drugs.
Methods
For current analyses, we analyzed the first 145 subjects
(83 men and 62 women) with Diabetes Mellitus type 2
not treated with insulin participating in the Use of Bicar-
bonate in Chronic Renal Insufficiency (UBI) study (NCT
NCT01640119) with at least 1 year of follow-up. The
UBI study protocol has been published previously [11].
Briefly, the UBI study is an on-going multi-center, open-
label, randomized controlled study designed to test the
impact of metabolic acidosis correction on CKD progres-
sion to End Stage Renal Disease (ESRD). CKD-3b-4 pa-
tients of 18 to 80 year of age, able to provide written
informed consent and serum bicarbonate levels below 24
mEql/l are randomized (allocation ratio 1:1) to either oral
sodium bicarbonate (treatment group) or conventional
therapy for CKD (control group). Study investigators are
free to adjust medications to achieve the targets for gly-
cated hemoglobin, bone mineral metabolism, blood pres-
sure, anemia, iron status, dyslipidemia as suggested by
guidelines on CKD patients’ management available at the
time of the study design [11]. The randomization process
is centralized to ensure allocation concealment. Patients
with evidence of neoplastic diseases, autoimmune dis-
eases, chronic heart failure NYHA class III-IV, uncon-
trolled arterial hypertension, severe peripheral arterial
disease (defined as limb amputation), cerebrovascular dis-
ease, neobladder or ureterosigmoidostomy, severe meta-
bolic acidosis (defined as serum bicarbonate <18 mEq/l)
or use of calcium carbonate in the 3-month prior to study
inclusion are excluded from the trial. Oral sodium bicar-
bonate is administered at the dose of 0.5 mmol/kg of body
weight (1 g of sodium bicarbonate contains 11.9 mmol –
initial dose about 3–4 g) two times a day until the achieve-
ment of the desired serum bicarbonate target of 24–
28 mmol/l. If a serum value of 28 mmol/l is exceeded, the
administration of bicarbonate is tapered each 3 days until
the desired serum target level is achieved [11].
Demographic, clinical and laboratory characteristics
Demographic and clinical characteristics were assessed
as study inception. Self-reported variables included age,
sex. Medical chart reviews were conducted to determine
the presence of diabetes mellitus status or the use of oral
antidiabetic medications, history of atherosclerotic car-
diovascular disease (ASCVD) and the use of different
medications. History of ASCVD was a composite meas-
ure that included myocardial infarction, angina, and per-
ipheral and cerebrovascular disease. Blood pressure was
measured after a 15 to 20 min rest, using a manual aner-
oid sphygmomanometer.
Routine biochemical laboratory measurements were
obtained at baseline and completion 12 months of
follow-up and analyzed at the facilities usual laboratories
as part of the standard patients care. All blood samples
were in a fasting condition. Insulin resistance was evalu-
ated via the Homeostatic Model Assessment (HOMA)
test at baseline and at completion of 12 months of
follow-up.
Finally, 25-OH vitamin D was measured every
3 months; the correction of low levels was started at
values lower than 20 ng/ml and stopped at values higher
than 50 ng/ml.
Patients using steroids and other drugs interfering dir-
ectly with glucose levels were excluded from the study.
Insulin resistance measurement and HOMA test
Insulin resistance was assessed indirectly by the Homeo-
static model assessment (HOMA) index as suggested by
Wallace and coworkers [12]. Briefly, the HOMA index is
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a mathematical model that allows to calculate insulin
sensitivity (HOMA-IR) and evaluate ß pancreatic cell
function (HOMA-%B) from fasting plasma glucose and
insulin levels [12]. It is a simple test, appropriate to per-
form in large epidemiological studies that nicely corre-
lates with experimental data obtained with direct
measurement techniques such as the euglycemic clamp
[13–16].
To perform the HOMA test, blood samples are
drawn twice (30 min apart) in 3 consecutive days. Pa-
tients are kept at rest, in a fasting status for at least
8 h before the blood sampling. Tobacco use is forbid-
den for the 12 h before blood tests. The presented
values for HOMA test at baseline and study comple-
tion are the mean values of the three consecutive
blood samples. For HOMA-IR and HOMA-%B calcu-
lation, the following formulas are used [12]:
– HOMA-IR = (FPI * FPG)/22.5;
– HOMA-%B = (20 * FPI)/(FPG - 3.5)
where FPI stands for fasting plasma insulin concentra-
tion (mU/l) and FPG stands for fasting plasma glucose
(mmol/l) (FPG conversion factor from mg/dl to mmol/l:
10.018).
HOMA-IR estimates of insulin resistance. Normal
values are <0.25. Values greater or equal than 5.5 indi-
cate insulin resistance typical of early stages of Diabetes
Mellitus. HOMA-B% estimates ß pancreatic cells func-
tion. It’s value ranges from 0 % (no pancreatic cell func-
tion) to 100 % (all pancreatic cell functioning). FPI and
FPG measurements were performed centrally at P.O. “A
Landolfi” – Solofra (AV), Italy, via COBAS 6000 or
COBAS C 501 (Roche Diagnostics) and IMMULITE
2000 (Siemens Healthcare Global), respectively.
Study objective and endpoint
Current analyses aim at testing the impact of metabolic
acidosis correction in CKD 3b-4 diabetic patients with
serum bicarbonate <24 mEq/l on insulin resistance eval-
uated via the Homeostatic Model Assessment (HOMA)
test. The HOMA was performed at study inception and
after 12 months of treatment with either oral sodium bi-
carbonate (treatment group) or conventional therapy for
CKD (control group).
Statistical analysis
Data are reported as mean ± SD or counts (percentage)
when appropriate. Un-paired T-test and Chi-square test
were used to assess difference between study groups at
baseline and study completion (Tables 1 and 2). The
bagplot (Fig. 1) was used to describe the bivariate associ-
ation of serum bicarbonate and HOMA test in subjects
randomized to oral sodium bicarbonate (treated) or
conventional therapy (controls) at study inception and
completion. Because of the random allocation to treat-
ment groups, the selection criterion was independent of
study investigators’ beliefs (i.e., we analyzed data of the
first 145 diabetic type 2 patients randomized in the UBI
study who completed 1 year of follow-up) and the the
optimal balance between groups at study inception, the
Wilcoxon rank sum test was used to assess between-
and within-group (treated vs control subjects) differ-
ences in HOMA-IR and HOMA-%B at study inception
as well as completion of 12 months of follow-up
(Table 3). Linear regression was used to assess the inde-
pendent association of treatment and/or metabolic acid-
osis correction and HOMA test at study completion.
First, we tested for the unadjusted association of (i)
treatment allocation, (ii) serum bicarbonate values at
follow-up and (iii) changes of serum bicarbonate (serum
bicarbonate at follow-up – serum bicarbonate at study
inception) with HOMA-IR (Table 4). Subsequently, we
tested the independent contribution of metabolic acidosis
correction (i.e., serum bicarbonate at study completion or
changes in serum bicarbonate) vs oral bicarbonate supple-
mentation, forcing both variables in the same regression
model (Table 4). However, due to the non-linear relation-
ship between serum bicarbonate (Fig. 2a) or changes in
serum bicarbonate (Fig. 2b) and HOMA index at study
completion, we tested for an interaction effect of treat-
ment and values of serum bicarbonate at study comple-
tion or changes of serum bicarbonates (Table 4). Because
of the significant effect modification of serum serum bi-
carbonate levels on treatment effect on HOMA test and
because at visual inspection (Fig. 2a) the association be-
tween serum bicarbonate and HOMA test was different
for values greater than 28 mmol/l, we performed some
additional analyses by applying regression splines with a
knot set at serum bicarbonate level of 28 mEq/l and tested
for the independent association between serum bicarbon-
ate, treatment and HOMA test at study completion
(Table 5). All analyses were conducted as intention-to-
treat. Two-tailed probability values ≤ 0.05 were considered
statistically significant. Analyses were completed using R
version 3.1.3 (2015-03-09) (The R Foundation for Statis-
tical Computing).
Results
A total of 145 (57 % men) diabetic type 2, middle-age
(65.5 ± 11.4 years) patients on oral antidiabetic medica-
tion were included in current analyses. At study incep-
tion, no significant differences in anthropometric,
clinical and laboratory characteristics between subjects
allocated to oral sodium bicarbonate or conventional
therapy were observed (Table 1). In particular, treated
subjects and controls exhibited similar renal function
(mean creatinine clearance: 32 ± 14 ml/min and 35 ±
Bellasi et al. BMC Nephrology  (2016) 17:158 Page 3 of 10
Table 1 Demographic, clinical, laboratory characteristics and use of oral anti-diabetic medications of patients randomized to oral
sodium bicarbonate (Treated) or conventional therapy (controls) at study inception
Overall Treated Control p-value
(N = 145) (N = 71) (N = 74)
Males, N (%) 83 (57 %) 47 (66 %) 36 (48 %) NS
Age, years 65.5 ± 11.4 64.9 ± 11.8 66.0 ± 12.9 NS
Body Weight, kg 75.5 ± 14.1 76.5 ± 14.6 73.4 ± 11.2 NS
Cardiovascular disease, N(%) 36 (25) 17 (24) 19 (26) NS
Systolic blood pressure, mmHg 122 ± 20 124 ± 19 120 ± 22 NS
Disatolic blood pressure, mmHg 73 ± 9 73 ± 8 73 ± 10 NS
Serum Bicarbonate, mEql/l 21.4 ± 1.9 21.2 ± 1.9 21.6 ± 2.0 NS
Serum Gucose, mg/dl 150 ± 44 149 ± 41 151 ± 47 NS
HbA1C % 6.76 ± 1.2 6.74 ± 1.0 6.8 ± 1.4 NS
Serum creatinine,mg/dl 2.1 ± 0.8 2.3 ± 0.8 2.0 ± 0.7 NS
BUN, mg/dl 87 ± 32 93 ± 35 81 ± 28 NS
Creatinine clearance, ml/min 33 ± 14 32 ± 14 35 ± 15 NS
Uric Acid, mg/dl 5.4 ± 1.8 5.6 ± 1.9 5.1 ± 1.8 NS
Serum sodium, mEql/l 139 ± 3 139 ± 3 139 ± 2 NS
Serum potassium, mEq/l 4.82 ± 0.7 4.85 ± 0.6 4.79 ± 0.7 NS
Total serum calcium, mg/dl 9.13 ± 0.6 9.14 ± 0.62 9.12 ± 0.58 NS
Serum phosphate, mg/dl 3.7 ± 0.7 3.8 ± 0.7 3.7 ± 0.7 NS
Serum albumin, g/dl 3.86 ± 0.42 3.85 ± 0.39 3.89 ± 0.46 NS
Hemoglobin, g/dl 12.3 ± 1.7 12.26 ± 1.82 12.39 ± 1.68 NS
C-Reactive Protein, mg/l 11.20 ± 28.1 11.08 ± 34.37 11.34 ± 18.53 NS
Serum PTH, pg/ml 122 ± 83 119 ± 34 124 ± 88 NS
Serum total cholesterol, mg/dl 154 ± 34 158 ± 34 151 ± 33 NS
Serum LDL cholesterol, mg/dl 91 ± 32 93 ± 31 87 ± 32 NS
Serum HDL cholesterol, mg/dl 45 ± 14 45 ± 12 45 ± 16 NS
Serum triglicerides, mg/dl 134 ± 58 130 ± 56 138 ± 60 NS
vitamin D (25-OH.D), ng/ml 39 ± 11 39 ± 10 38 ± 10 NS
Homa-IR 7.17 ± 2.4 7.13 ± 2.5 7.20 ± 2.36 NS
HOMA % B 49 ± 21 50 ± 22 48 ± 21 NS
Serum insulin, mcIU 18.3 ± 6.6 17.6 ± 6.1 19.0 ± 7.0 NS
Antidiabetic medications
Biguanides, number (%) 98 (67.5) 52 (73.2) 46 (62.2) NS
dose, mg/day 1740 ± 417 1760 ± 611 1725 ± 670 NS
Solfonylureas, number (%) 46 (31.7) 17 (23.9) 29 (39.2) NS
dose, mg/day 5.25 ± 1.19 5.29 ± 1.38 5.23 ± 1.14 NS
Meglitinides, number (%) 41 (28.3) 21 (29.6) 20 (27) NS
dose, mg/day 3.13 ± 1.35 3.52 ± 0.91 2.76 ± 1.59 NS
Use of > 1 medication, number (%) 37 (25.5) 20 (28.1) 17 (23) NS
Antihypertensive DRUGS
Furosemide, number (%) 131 (90.3) 62 (87.3) 69 (93.3) NS
dose, mg/day 55 ± 19 55 ± 21 55 ± 17 NS
ARB inhibitors, number (%) 75 (51.7) 37 (23.9) 38 (39.2) NS
ACE-Inhibitors, number (%) 74 (51) 38 (52.1) 36 (48.6) NS
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15 ml/min), serum bicarbonate levels (21.2 ±
1.9 mmol/l and 21.6 ± 2.0 mmol/l), fasting plasma
glucose levels (149 ± 41 mg/dl and 151 ± 47 mg/dl),
glycated hemoglobin (6.74 ± 1.0 % and 6.80 ± 1.4 %)
as well as serum insulin levels (17.6 ± 6.1 mcIU and
19.0 ± 7.0 mcIU) (Table 1). Overall, basal HOMA-IR
was 7.17 ± 2.4 and no difference between study
groups was noted (median [Interquartile range
(IQR)]: 6.4[5.5–7.9] and 6.4[5.5–8.2]; in the bicar-
bonate and control group, respectively). Of interest,
only 4 (5,6 %) and 6 (8.1 %) subjects in the bicar-
bonate and control group had a HOMA-IR <5. Fi-
nally, at baseline HOMA-%B was also comparable
between study groups (median [IQR]: 50.5 % [32.0–
67.2 %] and 43 % [32.7–62.2 %]; in the bicarbonate
and control group, respectively) (Table 1).
Table 1 shows patients’ antidiabetic and antihypertensive
drugs. Moreover, Table 1 shows 25-OH vitamin D: the two
groups did not show statistically significant differences of
vitamin D blood levels (39 ± 10 versus 38 ± 10 ng/ml, in
treated versus control, respectively)
Mean dose of oral bicarbonate administered was 0.7 ±
0.2 mmol/kg per each patient. At study inception there
were no differences between the two groups in the use
of oral antidiabetic drugs regarding number of pills,
doses, and type of drugs (Table 1). No adverse affects
were registered during oral bicarbonate administration.
At study completion, while no differences in renal
function and blood pressure control were observed, a
significant impact of oral sodium bicarbonate supplemen-
tation on serum bicarbonate levels (26.0 ± 2.0 vs 22.3 ±
1.9 mEq/l, in treated and control subjects, respectively) as
well as diabetes control and management was apparent
(Table 2). Specifically, HOMA-IR decreased in treated
(p for within group comparison: 0.004) but not control
subjects (p for within group comparison: 0.57) (median
[IQR]: 5.9 [5.0–7.0] and 6.3 [5.3–8.2]; p for between
groups comparison:0.01) (Fig. 1, Table 3). Similarly,
Table 1 Demographic, clinical, laboratory characteristics and use of oral anti-diabetic medications of patients randomized to oral
sodium bicarbonate (Treated) or conventional therapy (controls) at study inception (Continued)
Beta-blocker (%) 24 (16.5) 14 (19.7) 10 (13.5) NS
Other antihypertensive drugs number (%) 42 (28.9) 20 (28.2) 22 (29.7) NS
Use of > 1 medication, number (%) 70 (48.3) 38 (53.5) 32 (43.2) NS
Continuous and dichotomous variables are expressed as mean ± standard deviation or count (%), respectively
Table 2 Clinical, laboratory characteristics and use of anti-diabetic medications of patients randomized to oral sodium bicarbonate
(Treated) or conventional therapy (controls) at study completion
Overall Treated Control p-value
145 71 74
Body Weight, kg 76.1 ± 12.8 76.3 ± 12.8 73.4 ± 15.0 NS
Systolic blood pressure, mmHg 123 ± 17 125 ± 17 121 ± 16 NS
Disatolic blood pressure, mmHg 74 ± 8 76 ± 8 72 ± 10 NS
Serum Bicarbonate, mEql/l 24.2 ± 2.7 26.0 ± 2.0 22.3 ± 1.9 0.0001
Serum Gucose, mg/dl 118 ± 29 110 ± 32 127 ± 24 0.0001
HbA1C % 7.2 ± 2.9 6.7 ± 0.9 7.7 ± 3.7 0.028
Creatinine Clearance, ml/min 30 ± 16 32 ± 15 31 ± 16 NS
Homa-IR 6.52 ± 1.8 6.1 ± 1.5 7.0 ± 2.0 0.003
HOMA % B 52 ± 20 55 ± 18 49 ± 21 0.015
Serum insulin, mcIU 16.4 ± 6.6 13.4 ± 5.2 19.9 ± 6.3 0.0001
Antidiabetic medications
Biguanides, number (%) 89 (61.4) 45 (63.3) 44 (59.4) NS
dose, mg/day 1570 ± 517 1377 ± 457 1615 ± 550 0.005
Solfonylureas, number (%) 40 (27.6) 12 (16.9) 28 (37.8) 0.009
dose, mg/day 5.05 ± 1.29 4.89 ± 1.7 5.20 ± 1.07 0.033
Meglitinides, number (%) 36 (24.8) 16 (22.5) 20 (27) NS
dose, mg/day 3.13 ± 1.35 3.52 ± 0.91 2.76 ± 1.59 0.0001
Use of > 1 medication, number (%) 28 (19.3) 12 (16.9) 16 (21.6) NS
Continuous and dichotomous variables are expressed as mean ± standard deviation or count (%), respectively
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HOMA-%B increased (p for within group comparison:
0.036) in the experimental group (p for within group
comparison: 0.754) from a median [IQR] value of 50.5 %
[32.0 – 67.2 %] to 60.5 % [43.5 – 70.2 %] while it was
unchanged in the control group (median[IQR]: 43.0
[32.7 – 62.2] vs 45 [32.7 – 64.5] for baseline and follow-
up, respectively; p value for between comparison at
follow-up: 0.023) (Fig. 1, Table 3).
As documented in Fig. 2a and b, serum bicarbonate
levels or changes were not linearly associated with insu-
lin resistance. Improvement of serum levels of bicarbon-
ate was associated with HOMA improvement only if
metabolic acidosis over-correction (i.e., serum levels of
bicarbonate greater than 28 mEq/l) did not occur. In-
deed, a significant effect reduction (interaction test for
treatement*serum levels of bicarbonate: p = 0.013) of
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Fig. 1 The bagplots describe the association between serum bicarbonate and HOMA test in subjects randomized to oral sodium bicarbonate
(Treated) or conventional therapy (controls) at study inception and conclusion. Legend: The inner polygon (called bag) contains 50 % of all
points. Observations outside the outermost polygon (called fence) are outliers. The observations between the bag and fence are marked by line
segments. The asterisk symbol (*) near the center of the graph represents the bivariate median
Table 3 HOMA-IR and HOMA-%B at study inception and conclusion in treated and control subjects
Treated Control P value (between group)
HOMA-IR
Baseline 6.4 [5.5–7.9] 6.4 [5.5–8.2] 0.915
Study Completion 5.9 [5.0–7.0] 6.3 [5.3–8.2] 0.010
P-value (within group) 0.004 0.572
HOMA-%B
Baseline 50.5 [32.0–67.2] 43.0 [32.7–62.2] 0.543
Study Completion 60.5 [43.5–70.2] 45.0 [32.7–64.5] 0.023
P-value (within group) 0.036 0.754
Data are expressed as median [Interquartile range]. Wilcoxon rank sum test is used for between- and within-group comparisons
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oral bicarbonate supplementation on HOMA index oc-
curred as serum bicarbonate rose (Table 4). To explore
whether the effect on insulin resistance was due to the
oral bicarbonate administration per se or metabolic acid-
osis amelioration, we performed splines regression ana-
lyses to account for the change in the relationship
between serum bicarbonate levels and HOMA index ac-
cording to metabolic acidosis correction (i.e., below or
greater/equal than 28 mEq/l). As reported in Table 5,
the benefit associated with metabolic acidosis correction
disappeared when serum bicarbonate exceeded 28 mEq/
l. Notably, when treatment allocation and serum levels
of bicarbonate achieved were both forced into the spline
regression model, treatment allocation lost statistical sig-
nificance (p = 0.465) (Table 5), suggesting that metabolic
acidosis correction rather than oral bicarbonate supple-
mentation improves insulin resistance (Table 5).
Discussion
Current findings suggest that metabolic acidosis is linked
to insulin resistance in diabetic, Chronic Kidney Disease
(CKD) patients and oral bicarbonate administration may
correct metabolic acidosis that, in turn, improves insulin
sensitivity in this population.
Insulin resistance (or reduced insulin sensitivity) is
characterized by suboptimal biological responses of the
Table 4 Predictor of HOMA index at study completion by unadjusted and multivariable adjusted linear regression analyses
Predictor of HOMA index at study completion
Variable B-coef Standard Error P value
Unadjusted
- Treatment (yes vs no) −0.8740 0.3285 0.0087
Unadjusted
- Change in serum bicarbonate (%) −1.5833 0.9462 0.0964
Unadjusted
- Serum bicarbonate at study completion (mmol/l) −0.14511 0.06026 0.0173
Adjusted for treatment, change in serum bicarbonate
and interaction of change in serum bicarbonate*treatment
- Treatment (yes vs no) −1.4604 0.5015 0.00418
- Change in serum bicarbonate (%) −3.0382 1.8007 0.09378
- Interaction test (change in serum bicarbonate*treatment) 4.9948 2.3578 0.03591
Adjusted for treatment, serum bicarbonate at follow-up
and interaction of serum bicarbonate at followup*treatment
- Treatment (yes vs no) −11.6700 4.4255 0.00931
- Serum bicarbonate at follow-up (mmol/l) −0.2328 0.1106 0.03713
- Interaction test (serum bicarbonate at follow-up*treatment) 0.4476 0.1784 0.01325
*interaction between factors
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Fig. 2 The scatterplots represent the relationship between serum bicarbonate (a) and changes in serum bicarbonate (b) and HOMA index at
study completion. Legend: solid green line represents the linear regression line; solid red line represents the smoothed linear regression line
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liver, skeletal muscle and adipose tissue to normal
amounts of insulin secreted [4, 5, 17–19]. Several bio-
logical processes such as glucose, lipid or protein metab-
olism as well as single hormonal effects such as glycogen
synthesis or glucose oxidation may be affected in this
condition [20, 21]. Several factors may contribute to in-
sulin resistance in CKD. Visceral adipose tissue, diet,
low physical activity, cigarette smoking, drugs (glucocor-
ticosteroids, thiazide-like diuretics, beta-blockers) may
all contribute to insulin resistance [22–24]. However,
few lines of evidence also suggest that metabolic acid-
osis, that commonly complicates CKD, is implicated in
suboptimal biological responses to insulin [6, 25].
Hence, metabolic acidosis represents a modifiable risk
factor for insulin resistance and an attainable therapeutic
target in CKD [4]. Indeed, metabolic acidosis may exert
some detrimental effects at the cellular level inducing for
example an intra-extracellular shift of cations and in differ-
ent tissues such as bones and muscles as well as affect nu-
trition and metabolism [3, 6]. As part of CKD patients’ care,
alkali such as sodium bicarbonate administration and/or
low protein diet or diet rich in fruit and vegetables are com-
monly prescribed to avoid or correct metabolic acidosis.
Preliminary evidence suggests that metabolic acidosis
amelioration may attenuate CKD progression as well as
hard outcome [17, 26–28].
Our results confirm and expand previous efforts
[25, 29, 30] suggesting that metabolic acidosis correction
by sodium bicarbonate administration improves insulin re-
sistance without affecting the overall blood pressure control
(Table 2). This is likely due to the better response to insulin
of target organs (as suggested by the improvement of both
HOMA-IR and HOMA-%B). In contrast with previous
experiences [25, 29, 30], Ikizler and coworkers [31] recently
failed to demonstrate an association between metabolic
acidosis and insulin resistance in a cross-sectional, observa-
tional study of 42 patients with CKD stage 3–5. According
to these findings, a reduced acid burden improved meta-
bolic acidosis but not insulin sensitivity, measured via the
hyperinsulinemic euglycemic clamp method [31]. Although
we estimated rather than measured insulin resistance, our
results suggest that, at least in diabetic CKD patients, over-
correction of metabolic acidosis may also be detrimental
since values of serum bicarbonate greater than 28 mEq/l
are associated with decreased insulin sensitivity (Fig. 2).
While Ikizler and coworkers [31] define metabolic acidosis
as a dichotomous variable (i.e., serum bicarbonate level
<22 mEq/l), we prospectively explored the association of
serum bicarbonate as a continuous variable and insulin re-
sistance over a broad range of values of serum bicarbonate
(i.e., from 18 to 31 mEq/l). Current findings suggest that
this association is non-linear (Fig. 2) and insulin sensitivity
decreases for values of serum bicarbonate below 24 mEq/l
and above 28 mEq/l. Of interest, accounting for the non-
linear nature of the association also suggest that bicarbon-
ate levels rather than sodium bicarbonate per se, is respon-
sible for the effect on the HOMA index (Table 5).
In patients of treatment group assuming Biguanides
(45 subjects), bicarbonate administration was higher
(not significant) compared to other oral antidiabetic
drugs (0.79 ± 0.4 mmol/kg).
Although further work is needed to validate these results
in diabetic as well as non-diabetic CKD patients, the clinical
relevance of these findings should be evaluated in light of
the prevalence of insulin resistance and its associated com-
plications such as hyperinsulinemia, hyperglycemia and
hypertriglyceridemia [32]; the widespread use of sodium bi-
carbonate or alkali supplementation, low protein or vege-
tarian diet for CKD care [17, 33–40] as well as the safety
and relative inexpensiveness of the treatment tested. Aside
of confirming the link of bicarbonate and insulin resistance,
current results also provide with some guidance for CKD
patient care.
Our analyses suffer of a few limitations worth noting.
We investigated the relationship of insulin sensitivity and
metabolic acidosis in a subgroup of patients (diabetic pa-
tients on oral antidiabetic medications) randomized into
the Use of Bicarbonate in Chronic Renal Insufficiency
(UBI) study (NCT NCT01640119). This study aims at
testing the impact of alkali administration and acidosis
correction in diabetic and non-diabetic CKD patients on
renal function decline. Although we analyzed a subgroup
of patients, the analyses were carried out in the first 145
consecutive diabetic patients who completed at least 1
year of follow-up. This selection criterion as well as the ran-
dom assignment to treatment at study inception are inde-
pendent of the investigators’ beliefs and influences and we
Table 5 Predictor of HOMA index at study completion by
unadjusted and multivariable adjusted spline regression
analyses
Predictor of HOMA index at study completion (further elaborations)
Variable B-coef Standard
Error
P value
Unadjusted
- Serum bicarbonate <28 mmol/l at
follow-up
−4.6008 1.1804 0.00015
- Serum bicarbonate ≥28 mmol/l at
follow-up
1.9360 1.0270 0.06146
Adjusted for treatment, serum bicarbonate greater/equal or lower than
28 mmol/l
- Treatment (yes vs no) −0.3482 0.4757 0.4654
- Serum bicarbonate <28 mmol/l at
follow-up
−3.6980 1.7085 0.0321
- Serum bicarbonate ≥28 mmol/l at
follow-up
2.2055 1.0926 0.0454
Serum bicarbonate is used as a continuous variable and divided according
to ≥ 28 mmol/l (knot). The HOMA-serum bicarbonate levels relationship
changes for values of serum bicarbonate greater equal than 28 mmol/l
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can argue that current findings are similar to a randomized
clinical trial (RCT). The well balance of demographic, clin-
ical and laboratory characteristics between groups, further
corroborates this point. No power assumption or sample
size calculation was performed in light of the exploratory
nature of these analyses and the lack of similar data in this
domain. Insulin resistance is calculated rather than mea-
sured. However, the HOMA test is widely accepted as a reli-
able and reproducible tool to assess insulin sensitivity in
clinical and epidemiological studies [12–16, 41, 42].
Conclusions
In conclusion, current results corroborate the notion that
metabolic acidosis promotes insulin resistance and shed
some light on the impact of sodium bicarbonate adminis-
tration in CKD diabetic patients. Although further valid-
ation is mandatory, it seems that serum bicarbonate levels
rather than the treatment used is relevant to restore insu-
lin sensitivity. Finally, acidosis overcorrection (i.e., serum
bicarbonate levels >28 mEq/l) should be avoided since, as
metabolic acidosis, is associated with insulin resistance.
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